Last reviewed · How we verify
IM19
At a glance
| Generic name | IM19 |
|---|---|
| Sponsor | Beijing Immunochina Medical Science & Technology Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE) (NA)
- IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients (EARLY_PHASE1)
- Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia (EARLY_PHASE1)
- Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia (PHASE1, PHASE2)
- Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma (PHASE1, PHASE2)
- Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation (NA)
- Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients (PHASE1, PHASE2)
- Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IM19 CI brief — competitive landscape report
- IM19 updates RSS · CI watch RSS
- Beijing Immunochina Medical Science & Technology Co., Ltd. portfolio CI